Intersecting guidelines: Administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer

Charles L. Bennett, Pamela S. Becker, Eric H. Kraut, Athena T. Samaras, Dennis P. West

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

There has been a dramatic sea change in the use of erythropoiesis- stimulating agents (ESAs) for anemic persons with chronic kidney disease (CKD) or cancer patients undergoing chemotherapy. An important area that has not been addressed previously is a CKD patient who also has a malignancy. Clinical guidelines exist that outline recommended treatments for each disease, but the intersection of the two disease processes presents difficult decisions for patients and physicians. Herein, we review the background underlying recent revisions in clinical alerts and guidelines for ESAs, and provide guidance for treating anemia among CKD patients who are receiving no therapy, chemotherapy with curative intent, or chemotherapy with palliative intent. The guiding principle is that comprehensive assessment of risks and benefits in the relevant clinical setting is imperative. Journal compilation

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalSeminars in Dialysis
Volume22
Issue number1
DOIs
StatePublished - Jan 2009

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Intersecting guidelines: Administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer'. Together they form a unique fingerprint.

Cite this